FDA approves Portola's Andexxa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) added about $570 million in market cap on May 4 after FDA granted accelerated approval to a resubmitted BLA for its Andexxa andexanet alfa.

The agency approved Andexxa to reverse the

Read the full 349 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE